Our website may collect personal information, for example: email.
Our website uses the information in order to provide the best possible service, particularly to maintain a user registry. It is possible that periodic emails are sent through our site with a summary of news and events, these emails will be sent to the address you provide and may be canceled at any time. WebCim is highly committed to fulfill the commitment to keep your information secure.
This website may contain links to other sites that may be of interest to you. Once you click on these links and leave our site, we no longer have control over the site to which you are redirected and therefore we are not responsible for the terms or privacy or the protection of your data in those other third party sites. These sites are subject to their own privacy policies, so it is recommended that you consult them to confirm that you agree with them.
¡Stay informed of our latest news!
CIMAvax EGF ® is a therapeutic vaccine registered in Cuba (developed by the Center of Molecular Immunology (CIM), for advanced lung cancer. This therapeutic vaccine has a health history in the indication: Advanced non-small cell lung cancer (NSCLC) stage IIIb and IV, after the first line of chemotherapy. It is in this condition and type of lung cancer that the greatest clinical benefit is obtained in terms of increased survival and improved quality of life, as well as a broad safety profile in treated patients. This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary pulmonary, because we have no evidence of efficacy to date. It is necessary to know the histology and tumor stage of the patient, since CIMAvax EGF ® is only registered for non-small cell lung cancer of advanced stage IIIb and IV cells (NSCLC), in other types of tumors we have no evidence of clinical efficacy .
Questions of Interest:
Position of CIM for CIMAvax EGF®:
The Center for Molecular Immunology (CIM) is the center where it develops, produces and markets this medicine among other biotechnological products. This institution does not offer treatments to patients directly, nor does it inform about the price of the products they produce.
Foreign patients should contact the Cuban Medical Services who will evaluate each case if they are susceptible to treatment with these vaccines and receive it within a comprehensive program of patient care with commercial value.
You can contact them at these addresses:
At the International Clinic La Pradera:
Phones (537) 2737467 ext. 403
If you want a treatment outside of Cuba:
Laboratorio Libra Paraguay S.A
Dirección: Pedro Ciancio 1443 entre Santiago y San Cosme B Jara Asunción Persona de Contacto: Sr. Pablo Moreira Gerente Comercial
Correo electrónico: email@example.com
Teléfono: (595-21) 228 370
Móvil: (595) 986 679300
Sr. Alejandro Castaño.
Tel: + 57-4-334 40 33
Móvil: +57 - 311 301 8257
Cra.46 # 19 sur 117
Medellín, Colombia, América del Sur
Laboratorio Elea Phoenix S.A.
Sanabria 2353 (C1417AZE), Ciudad Autónoma de Buenos Aires, Argentina
Tel. (5411) 4379 4300 (int. 1266)
Director médico Dr. Matias DEPRATI
050033, Almaty, Khodzhanova street, 13 house, 69
CEO. Alina Ilimbayeva
+7 701 715 6000
Kraljice Natalije 46
Tel: +381 11 36 28 433
CEO. Mr. Zoran Vujovic.
Si necesita cualquier información adicional, no dude en contactarnos.